Premium
Bioactive peptides and proteins as alternative antiplatelet drugs
Author(s) -
Rengasamy Kannan R.R.,
Khan Haroon,
Ahmad Imad,
Lobine Devina,
Mahomoodally Fawzi,
Suroowan Shanoo,
Hassan Sherif T.S.,
Xu Suowen,
Patel Seema,
Daglia Maria,
Nabavi Seyed Mohammad,
Pandian Shunmugiah Karutha
Publication year - 2019
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21579
Subject(s) - prasugrel , ticagrelor , clopidogrel , medicine , pharmacology , platelet aggregation inhibitor , drug , aspirin , platelet aggregation , antiplatelet drug , platelet , immunology
Antiplatelet drugs reduce the risks associated with atherothrombotic events and show various applications in diverse cardiovascular diseases including myocardial infarctions. Efficacy of the current antiplatelet medicines including aspirin, clopidogrel, prasugrel and ticagrelor, and the glycoprotein IIb/IIIa antagonists, are limited due to their increased risks of bleeding, and antiplatelet drug resistance. Hence, it is important to develop new effective antiplatelet drugs, with fewer side‐effects. The vast repertoire of natural peptides can be explored towards this goal. Proteins and peptides derived from snake venoms and plants represent exciting candidates for the development of novel and potent antiplatelet agents. Consequently, this review discusses multiple peptides that have displayed antiplatelet aggregation activity in preclinical drug development stages. This review also describes the antiplatelet mechanisms of the peptides, emphasizing the signaling pathways intervened by them. Also, the hurdles encountered during the development of peptides into antiplatelet drugs have been listed. Finally, hitherto unexplored peptides with the potential to prevent platelet aggregation are explored.